Patents Examined by Marcos L Sznaidman
  • Combinations of cannabinoids and N-acylethanolamines
    Patent number: 11197845
    Abstract: The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: December 14, 2021
    Assignee: SciSparc Ltd.
    Inventors: Ephraim Brener, Elran Haber, Ascher Shmulewitz
  • Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
    Patent number: 11192852
    Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: December 7, 2021
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Eric Anderson, Gary L. Bolton, Bradley Caprathe, Xin Jiang, Chitase Lee, William H. Roark, Melean Visnick
  • Amino pyrimidine derivatives
    Patent number: 11180460
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: November 23, 2021
    Assignee: Novartis AG
    Inventors: Daniela Angst, Francois Gessier, Anna Vulpetti
  • Essential oil of with a high geraniol content, and use for treating greasy skin and/or the associated aesthetic defects
    Patent number: 11179316
    Abstract: The present invention relates to an essential oil of Satureja montana comprising more than 60% by weight of geraniol and more than 5% by weight of trans-?-caryophyllene, in particular of Satureja montana L. ssp. variegata. The present invention also relates to the cosmetic use of an essential oil of Satureja montana comprising more than 60% by weight of geraniol and more than 5% by weight of trans-?-caryophyllene, in particular of Satureja montana L. ssp. variegata, for treating greasy skin and/or preventing greasy or greasy-prone skin and/or the associated aesthetic skin defects. The invention also relates to a cosmetic composition comprising said oil, to a non-therapeutic cosmetic care and/or cleansing treatment process for greasy skin, and also to said essential oil as a dermatological agent.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: November 23, 2021
    Assignee: L'OREAL
    Inventors: Géraldine Lerebour, Pierre Lartaud, Bertrand Lacroix
  • Dermatophytosis prophylaxis and treatment
    Patent number: 11154527
    Abstract: A composition and method for the prophylaxis and treatment of topical fungal infections is provided. Generally, the composition includes an HMG-CoA reductase inhibitor and a carrier. In some forms, the composition further includes an anti-fungal agent. The method generally includes the steps of applying the composition topically once or multiple times. The composition and method can be used in combination with another form of fungal treatment, such as oral medications.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: October 26, 2021
    Assignee: The Children's Mercy Hospital
    Inventors: Susan Abdel-Rahman, Barry L. Preuett, J. Steven Leeder
  • Dual active parasiticidal granule compositions, methods and uses thereof
    Patent number: 11147273
    Abstract: The present invention encompasses a stabilized parasiticidal granule composition comprising a macrocyclic lactone compound and an insect growth regulator. The invention also encompasses methods of making and methods of using the granule for treating, controlling or preventing parasitic infestation or parasitic infection in an animal.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: October 19, 2021
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Kour Chand Jindal, Jian Han, Kim Agnew
  • Methods for the diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in canines
    Patent number: 11143660
    Abstract: The invention relates to methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in canines, comprising measuring inflammatory biomarkers wherein elevated levels of the biomarkers in blood correlates to reduced inflammation and reduced levels in blood correlates to increase level in the tissues. The invention further provides a method to treat or control inflammation comprising administering a diet comprising increased levels of one or more of DHA, EPA, vitamin C, vitamin E, and/or L-carnitine.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: October 12, 2021
    Assignee: Hills Pet Nutrition, Inc.
    Inventor: Nolan Frantz
  • Opioid ketal compounds and uses thereof
    Patent number: 11130765
    Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently H or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: September 28, 2021
    Assignee: Rhodes Technologies
    Inventors: Robert J. Kupper, Raymond C. Glowaky
  • Metal delivery agents and therapeutic uses of the same
    Patent number: 11123350
    Abstract: The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels). Conditions in of this type include cancer and conditions characterised by or associated with oxidative damage, more specifically neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease or Huntington's disease. The invention also relates to ligands useful in the preparation of metal complexes of this type.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: September 21, 2021
    Assignee: The University of Melbourne
    Inventors: Paul Donnelly, James Hilton, Peter Crouch
  • Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders
    Patent number: 11110104
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification, for use in treating cognitive deficits and/or psychiatric disorders, such as those associated with neurological or neurodegenerative disorders, psychiatric or mood disorders, and HIV-associated neurocognitive disorders (HAND). Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: September 7, 2021
    Assignees: The Johns Hopkins University, Icahn School of Medicine at Mount Sinai
    Inventors: Barbara Slusher, David Volsky, Mike Nedelcovych, Kristen Hollinger, Atsushi Kamiya
  • Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy
    Patent number: 11090290
    Abstract: The present invention pertains to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and Clonidine and/or Clonidine derivatives as a sole active ingredient for use in the prevention of skin injury resulting from radiotherapy by transmucocal administration.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: August 17, 2021
    Assignee: MONOPAR THERAPEUTICS, INC.
    Inventors: Bérangère Vasseur-Demarcy, Pierre Attali
  • Opioid ketal compounds and uses thereof
    Patent number: 11091496
    Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 17, 2021
    Assignee: RHODES TECHNOLOGIES
    Inventors: Robert J. Kupper, Raymond C. Glowaky
  • Compositions comprising triterpenoids
    Patent number: 11083736
    Abstract: The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating stroke or trauma and side effects related thereto.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: August 10, 2021
    Assignee: REGENERA PHARMA LTD.
    Inventors: Zadik Hazan, Konstantin Adamsky, Andre C. B. Lucassen, Nurit Novak
  • Treatment of hypertension by renal vascular delivery of guanethidine
    Patent number: 11083877
    Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or sympathetic nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: August 10, 2021
    Assignee: MERCATOR MEDSYSTEMS, INC.
    Inventor: Kirk Patrick Seward
  • Dermatomycosis treatment agent
    Patent number: 11083701
    Abstract: Provided is a means effective in treating dermatomycosis. An external therapeutic agent for treating dermatomycosis containing a trialkali metal salt of citric acid.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: August 10, 2021
    Inventor: Shiro Yoshizaki
  • Heteroaryl amides as inhibitors of protein aggregation
    Patent number: 11078196
    Abstract: The present invention relates to certain heteroaryl amide compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer and melanoma.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: August 3, 2021
    Assignee: UCB Biophama SRL
    Inventors: Wolfgang Wrasidlo, Emily M. Stocking
  • Quinolone derivatives as fibroblast growth factor receptor inhibitors
    Patent number: 11078199
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: August 3, 2021
    Assignee: PRINCIPIA BIOPHARMA, INC.
    Inventors: Erik Verner, Kenneth Albert Brameld
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 11065219
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: July 20, 2021
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Anti-microbial compositions comprising cannabinoids
    Patent number: 11058646
    Abstract: This invention discloses anti-bacterial and anti-fungal compositions in spray form, in cream form, in liquid form, and in powder form. The anti-bacterial and anti-fungal compositions comprise cannabinoids, specifically cannabidiol, cannabigerol, tetrahydrocannabinol, tetracannabidivarin, and/or cannabidivarin for anti-bacterial and anti-fungal activities. The anti-bacterial and anti-fungal compositions may be used to treat toe nail fungus, MRSA infection, herpes virus infection, tinea pedis, burn wound infections, sun burns, diabetic infections, eczema, impetigo, dermatophytosis, psoriasis, itchy skin, atopic dermatitis, dandruff, and general topical infections.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: July 13, 2021
    Assignee: APIRx Pharmaceutical USA, LLC
    Inventors: George E. Anastassov, Lekhram Changoer, Philippus Anne Van Damme
  • Application of substances containing AuCs in preparing medicine for preventing and treating Alzheimer's disease
    Patent number: 11058717
    Abstract: Disclosed are a pharmaceutical use of a gold cluster and a substance containing the gold cluster and the preparation method and use thereof. The gold cluster and substance containing the gold cluster can inhibit the aggregation of A? and ?-syn, has excellent effects on the levels of cell models and animal models, and can be used to prepare drugs for preventing and treating Alzheimer's disease and/or Parkinson's disease.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: July 13, 2021
    Assignee: Shenzhen Profound-View Pharma Tech Co., Ltd
    Inventor: Taolei Sun